Check out what's new in TB treatment today! Head over to buff.ly/8xN6tLT for what's new in the ATS/CDC/ERS/IDSA 2025 guidelines for both drug-susceptible and drug-resistant TB!
Infectious Disease Society of America issues a statement on the political interference with the CDC vaccine information and the advisory committee on immunisation www.idsociety.org/news--public...
Short versus long treatment duration for streptococcal bloodstream infection (no significant differences...) #IDsky bit.ly/4gQz5Rv
1. Did you know that Girl Scouts has, for a long time, accepted trans girls and nonbinary scouts?
Trans kids are under attack. Every year, I make a thread of trans and nonbinary girl scouts you can get your cookies from.
Lets get our cookies from them this year in solidarity!
Did You Know: penicillin G benzathine and procaine combined comes in TWO different formulations that are NOT interchangeable? One (Bicillin C-R 900/300) has benzathine and procaine in a 3:1 ratio while the other (Bicillin C-R) has 1:1 ratio. Bicillin C-R 900/300 is only for infants+children! #IDSky
Going to start trying to post something new I learn each week. Welcome further discussion from #IDSky (especially if what I thought I learned was incorrect!)
Today’s pearl: cefiderocol seems to have decent CNS penetration - CSF to Plasma AUC0-8h =44% according to one publication (JAC 2022;77:1787-9)
editorial from @bmj.com and paper: Poor staff retention is associated with higher patient mortality. Have said it before & I’ll say it again. If you don’t care for the carers, they cannot care for their patients.
www.bmj.com/content/387/...
ABX durations for secondary peritonitis and acute cholecystitis and cholangitis
🌟 ABX Pearl of the Day: Duration of treatment in intra-abdominal infections (IAI)! 💊
💡 Q: How long should I treat IAI after source control?
🔍 A: While STOP-IT trial calls for 4 days post-source control, there are notable exceptions. See infographic for details 👇
#IDsky #AMSsky #MedSky #Pharmsky
Great suggestion! We just submitted there earlier this month and unfortunately were not successful. Hoping for success with a different journal!
This came up recently for me and Jeff though with NTM… The easy answer might be ampho but of course has its own issues. Short of throwing our hands up, we were leaning rifabutin/posa vs. withholding treatment for NTM while managing aspergillosis and resume later.Then I went on vacation for a week 😂
We employed a collegial approach in this initiative - The e-message was not associated with any patient chart, nor did it challenge specific antibiotic decisions. The purpose is purely to make clinicians aware that their patient later developed C diff and encourage reflection on antibiotic use
Hey #IDSky! ~4 years ago our ASP began sending a standard e-message to providers who cared for a patient <7 days before developing HA-CDI but were not on service when tested as a way to close the loop. We summarized our experience and e-message in a manuscript - any recs for a journal to submit to?
US Antibiotic Awareness Week #USAAW24 is here!
MAD-ID is proud to support antibiotic stewards through training, educational grants, online resources, member promotion, and more!
https://buff.ly/41bOU1l #IDSky #MedSky #PharmSky
#MADID was the first ID conference I ever went to, and still is one of my favorite ID/ASP conferences each year. I always recommend it to pharmacy residents who have an interest in ID. Always great content delivered by experts in the field! #IDSky
happy #antibioticawarenessweek!🦠
sharing a paper I ❤️ from Dr. Dinh, a lovely human who told me they noticed in their RCTs that some patients were getting exclusive PO treatment for CAP (dealers choice!) They explored these pts and its worth a read #idsky #pharmsky
pubmed.ncbi.nlm.nih.gov/38734138/
Want to learn about the treatment of RVI in immunocompromised patients?
Join us for the next @ESCMID.bsky.social ESGICH/ESGREV webinar on the treatment of RVI.
Chairs: Hans Hirsch and @michaelisonmd.bsky.social
Talks by: Pauline Vetter, Jose Luise Pinana, Fareed Khawaja
Collaboration between antimicrobial stewardship programs and the microbiology lab are fundamentally important to guiding clinicians towards the optimal therapy! Fortunate to work with Dr. Bobenchik on our medicine grand rounds from this past week, and thrilled by the number of attendees! #IDSky
for our new #IDsky #Medsky friends, @sidpharm.bsky.social creates an ID & stewardship podcast called Breakpoints. here’s one of my favorite episodes featuring the amazingly smart and kind Robert Bonomo and Ryan Shields teaching us all things enzymatic resistance podcasts.apple.com/us/podcast/b...
